These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16920540)

  • 21. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.
    Gibellini D; Borderi M; De Crignis E; Cicola R; Cimatti L; Vitone F; Chiodo F; Re MC
    J Infect; 2008 Mar; 56(3):219-25. PubMed ID: 18276011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
    Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L
    AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
    Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
    Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
    J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration.
    Jaroszewicz J; Wiercinska-Drapalo A; Lapinski TW; Prokopowicz D; Rogalska M; Parfieniuk A
    Antivir Ther; 2006; 11(5):641-5. PubMed ID: 16964834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study.
    Pantanowitz L; Bohac G; Cooley TP; Aboulafia D; Dezube BJ
    BJU Int; 2008 Jun; 101(12):1519-23. PubMed ID: 18384640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between pharmacy medication refill-based adherence rates and cd4 count and viral-load responses: A retrospective analysis in treatment-experienced adults with HIV.
    Townsend ML; Jackson GL; Smith R; Wilson KH
    Clin Ther; 2007 Apr; 29(4):711-6. PubMed ID: 17617294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of salivary factors in persistent oral carriage of Candida in humans.
    Hibino K; Samaranayake LP; Hägg U; Wong RW; Lee W
    Arch Oral Biol; 2009 Jul; 54(7):678-83. PubMed ID: 19439266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
    HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.